Dr. Lubomir Sokol, MD

Dr. Sokol practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Sokol's NPI, 1376558957, was assigned on July 30, 2006. Dr. Sokol graduated from University Karlovy, Lek Fak Ii in 1981. Dr. Sokol holds Florida license ME80388.

Dr. Sokol's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Sokol also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Sokol's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Dr. Sokol is also affiliated with Tampa General Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Sokol to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sokol practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Sokol's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Sokol is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Sokol's licenses on file in 2 states: Florida and Louisiana.

Dmand AI lists chronic anemia and lymphoma among the conditions Dr. Sokol treats.

CMS data shows 105 Medicare services from Dr. Sokol across 3 procedure codes in 2024, for 98 Medicare patients. Medicare paid $7,697 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 98 Medicare patients who saw Dr. Sokol in 2024. The largest group is 65 to 74, with 44 patients. 75% of them have high cholesterol, and 73% have high blood pressure. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sokol's median patient age at 68, with 45% women.

In 2024, Dr. Sokol wrote 62 Medicare Part D claims for 24 patients. 73% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $70,000 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Sokol for performance year 2024, reported as part of a group. Dr. Sokol accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sokol as offering telehealth.

Dmand AI links 167 papers to Dr. Sokol, published from 2004 to 2025. 2016 was the busiest year, with 9. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Myelodysplastic Syndromes and Antineoplastic Agents. Dr. Sokol has published most often in Cancer Control. Dr. Sokol's most frequent co-authors are Julio C. Chavez, MD, Samir Mukundray Dalia, MD and Celeste M. Bello, MD.

Dmand AI links Dr. Sokol to 9 clinical trials, 5 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphatic Diseases and Leukemia, B-Cell. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 5.

CMS Open Payments shows 52 general payments to Dr. Sokol from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. Kyowa Kirin, Inc. paid the most, $6,271. It also lists 1 research payment totaling $1,564 in 2016.

Dmand AI lists 2 awards for Dr. Sokol, most recently America's Top Doctors in 2014.

Dr. Sokol graduated from University Karlovy, Lek Fak Ii in 1981.

Dr. Sokol is in network with 8 carriers, including Excellus BlueCross BlueShield, Blue Cross Blue Shield of Michigan and Humana. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.